Prognostic Value of Soluble Programmed Cell Death Ligand-1 (sPD-L1) in Various Cancers: A Meta-analysis

Overview

Journal Target Oncol

Specialty Oncology

Date 2020 Nov 22

PMID 33222017

Citations 8

Authors

Xiaoyang Li

Yu Zheng

Fei Yue

Affiliations

Soon will be listed here.

Abstract

Background: The prognostic value of soluble programmed cell death ligand-1 (sPD-L1) in patients with cancer has been inconsistent across previous studies.

Objective: This meta-analysis aimed to investigate the prognostic significance of sPD-L1 in human tumors.

Methods: A comprehensive search of PubMed, Web of Science, Embase, and Cochrane databases from inception to January 6, 2020 was conducted. Studies of sPD-L1 measured by enzyme-linked immunosorbent assay (ELISA) that had available hazard ratios (HRs) for survival outcomes based on high or low sPD-L1 levels were included. The primary endpoint was long-term survival, namely, overall survival (OS), and the second endpoint was short-term survival, including progression-free survival (PFS), disease-free survival (DFS), recurrence-free survival (RFS), and cancer-specific survival (CSS).

Results: A total of 21 studies, with 2413 patients, were included in this meta-analysis. Elevated sPD-L1 was associated with worse OS [HR = 2.46, 95% confidence interval (CI) 1.74-3.49, P < 0.001]. Moreover, high sPD-L1 was predictive of worse PFS/DFS/RFS/CSS (HR = 2.22, 95% CI 1.47-3.35, P < 0.001). High sPD-L1 was consistently correlated with poor OS and PFS/DFS/RFS/CSS irrespective of study design, sample, and cut-off value of sPD-L1. However, there was non-significant correlation between sPD-L1 and sex, age, clinical stage, Eastern Cooperative Oncology Group Performance Status, tumor differentiation, or serum lactate dehydrogenase.

Conclusions: This meta-analysis showed that sPD-L1 was correlated with poor prognosis in human tumors. In addition, sPD-L1 could be used as a predictive factor of inferior outcomes during multiple malignancy treatments.

Citing Articles

Prognostic and clinicopathological role of soluble programmed cell death ligand-1 in patients with diffuse large B-cell lymphoma: a meta-analysis.

Lu H, Luo L, Mi J, Sun M, Wang H, Wang Z Front Oncol. 2025; 15:1506799.

PMID: 39959666 PMC: 11825807. DOI: 10.3389/fonc.2025.1506799.

Prognostic significance of blood-based PD-L1 analysis in patients with non-small cell lung cancer undergoing immune checkpoint inhibitor therapy: a systematic review and meta-analysis.

Cui Q, Li W, Wang D, Wang S, Yu J World J Surg Oncol. 2023; 21(1):318.

PMID: 37821941 PMC: 10566159. DOI: 10.1186/s12957-023-03215-2.

The predictive role of soluble programmed death ligand 1 in digestive system cancers.

Ruan J, Zhao Z, Qian Y, Xu R, Liao G, Kong F Front Oncol. 2023; 13:1170220.

PMID: 37519785 PMC: 10374258. DOI: 10.3389/fonc.2023.1170220.

Prognostic value of soluble programmed cell death ligand-1 (sPD-L1) in lymphoma: a systematic review and meta-analysis.

Ding Y, Sun C, Hu L, Xiong S, Zhai Z Ann Hematol. 2023; 102(9):2425-2434.

PMID: 37382610 DOI: 10.1007/s00277-023-05325-z.

Immune Checkpoint Profiling in Humanized Breast Cancer Mice Revealed Cell-Specific LAG-3/PD-1/TIM-3 Co-Expression and Elevated PD-1/TIM-3 Secretion.

Bruss C, Kellner K, Albert V, Hutchinson J, Seitz S, Ortmann O Cancers (Basel). 2023; 15(9).

PMID: 37174080 PMC: 10177290. DOI: 10.3390/cancers15092615.

References

Bray F, Ferlay J, Soerjomataram I, Siegel R, Torre L, Jemal A . Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68(6):394-424. DOI: 10.3322/caac.21492. View

Fitzmaurice C, Abate D, Abbasi N, Abbastabar H, Abd-Allah F, Abdel-Rahman O . Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2017: A Systematic Analysis for the Global Burden of Disease Study. JAMA Oncol. 2019; 5(12):1749-1768. PMC: 6777271. DOI: 10.1001/jamaoncol.2019.2996. View

Constantinidou A, Alifieris C, Trafalis D . Targeting Programmed Cell Death -1 (PD-1) and Ligand (PD-L1): A new era in cancer active immunotherapy. Pharmacol Ther. 2018; 194:84-106. DOI: 10.1016/j.pharmthera.2018.09.008. View

Dermani F, Samadi P, Rahmani G, Kohlan A, Najafi R . PD-1/PD-L1 immune checkpoint: Potential target for cancer therapy. J Cell Physiol. 2018; 234(2):1313-1325. DOI: 10.1002/jcp.27172. View

Balar A, Weber J . PD-1 and PD-L1 antibodies in cancer: current status and future directions. Cancer Immunol Immunother. 2017; 66(5):551-564. PMC: 11028560. DOI: 10.1007/s00262-017-1954-6. View

Wu P, Wu D, Li L, Chai Y, Huang J . PD-L1 and Survival in Solid Tumors: A Meta-Analysis. PLoS One. 2015; 10(6):e0131403. PMC: 4483169. DOI: 10.1371/journal.pone.0131403. View

Pyo J, Kang G, Kim J . Prognostic role of PD-L1 in malignant solid tumors: a meta-analysis. Int J Biol Markers. 2016; 32(1):e68-e74. DOI: 10.5301/jbm.5000225. View

Tang C, Chang J . PD-L1 expression in lung cancer. J Thorac Dis. 2017; 8(11):3053-3055. PMC: 5179422. DOI: 10.21037/jtd.2016.11.38. View

Huang S, Lin H, Lin C, Li C, Yao M, Tang J . Soluble PD-L1: A biomarker to predict progression of autologous transplantation in patients with multiple myeloma. Oncotarget. 2016; 7(38):62490-62502. PMC: 5308741. DOI: 10.18632/oncotarget.11519. View

10.

Gong B, Kiyotani K, Sakata S, Nagano S, Kumehara S, Baba S . Secreted PD-L1 variants mediate resistance to PD-L1 blockade therapy in non-small cell lung cancer. J Exp Med. 2019; 216(4):982-1000. PMC: 6446862. DOI: 10.1084/jem.20180870. View

11.

Rossille D, Gressier M, Damotte D, Maucort-Boulch D, Pangault C, Semana G . High level of soluble programmed cell death ligand 1 in blood impacts overall survival in aggressive diffuse large B-Cell lymphoma: results from a French multicenter clinical trial. Leukemia. 2014; 28(12):2367-75. DOI: 10.1038/leu.2014.137. View

12.

Zheng Z, Bu Z, Liu X, Zhang L, Li Z, Wu A . Level of circulating PD-L1 expression in patients with advanced gastric cancer and its clinical implications. Chin J Cancer Res. 2014; 26(1):104-11. PMC: 3937742. DOI: 10.3978/j.issn.1000-9604.2014.02.08. View

13.

Zhang J, Gao J, Li Y, Nie J, Dai L, Hu W . Circulating PD-L1 in NSCLC patients and the correlation between the level of PD-L1 expression and the clinical characteristics. Thorac Cancer. 2015; 6(4):534-8. PMC: 4511334. DOI: 10.1111/1759-7714.12247. View

14.

Fukuda T, Kamai T, Masuda A, Nukui A, Abe H, Arai K . Higher preoperative serum levels of PD-L1 and B7-H4 are associated with invasive and metastatic potential and predictable for poor response to VEGF-targeted therapy and unfavorable prognosis of renal cell carcinoma. Cancer Med. 2016; 5(8):1810-20. PMC: 4971909. DOI: 10.1002/cam4.754. View

15.

Takahashi N, Iwasa S, Sasaki Y, Shoji H, Honma Y, Takashima A . Serum levels of soluble programmed cell death ligand 1 as a prognostic factor on the first-line treatment of metastatic or recurrent gastric cancer. J Cancer Res Clin Oncol. 2016; 142(8):1727-38. DOI: 10.1007/s00432-016-2184-6. View

16.

Sideras K, de Man R, Harrington S, Polak W, Zhou G, Schutz H . Circulating levels of PD-L1 and Galectin-9 are associated with patient survival in surgically treated Hepatocellular Carcinoma independent of their intra-tumoral expression levels. Sci Rep. 2019; 9(1):10677. PMC: 6650499. DOI: 10.1038/s41598-019-47235-z. View

17.

Wei W, Xu B, Wang Y, Wu C, Jiang J, Wu C . Prognostic significance of circulating soluble programmed death ligand-1 in patients with solid tumors: A meta-analysis. Medicine (Baltimore). 2018; 97(3):e9617. PMC: 5779759. DOI: 10.1097/MD.0000000000009617. View

18.

Ding Y, Sun C, Li J, Hu L, Li M, Liu J . The Prognostic Significance of Soluble Programmed Death Ligand 1 Expression in Cancers: A Systematic Review and Meta-analysis. Scand J Immunol. 2017; 86(5):361-367. DOI: 10.1111/sji.12596. View

19.

Moher D, Liberati A, Tetzlaff J, Altman D . Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol. 2009; 62(10):1006-12. DOI: 10.1016/j.jclinepi.2009.06.005. View

20.

Tierney J, Stewart L, Ghersi D, Burdett S, Sydes M . Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007; 8:16. PMC: 1920534. DOI: 10.1186/1745-6215-8-16. View